Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?

The live attenuated Japanese encephalitis (JE) vaccine SA14-14-2 has been used in Nepal for catch-up campaigns and is now included in the routine immunisation schedule. Previous studies have shown good vaccine efficacy after one dose in districts with a high incidence of JE. The first well-documente...

Full description

Saved in:
Bibliographic Details
Published inPLoS neglected tropical diseases Vol. 13; no. 4; p. e0007269
Main Authors Turtle, Lance, Brindle, Hannah E., Schluter, W. William, Faragher, Brian, Rayamajhi, Ajit, Bohara, Rajendra, Gurung, Santosh, Shakya, Geeta, Yoksan, Sutee, Dixit, Sameer, Rajbhandari, Rajesh, Paudel, Bimal, Adhikari, Shailaja, Solomon, Tom, Griffiths, Mike J.
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.04.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The live attenuated Japanese encephalitis (JE) vaccine SA14-14-2 has been used in Nepal for catch-up campaigns and is now included in the routine immunisation schedule. Previous studies have shown good vaccine efficacy after one dose in districts with a high incidence of JE. The first well-documented dengue outbreak occurred in Nepal in 2006 with ongoing cases now thought to be secondary to migration from India. Previous infection with dengue virus (DENV) partially protects against JE and might also influence serum neutralising antibody titres against JEV. This study aimed to determine whether serum anti-JEV neutralisation titres are: 1. maintained over time since vaccination, 2. vary with historic local JE incidence, and 3. are associated with DENV neutralising antibody levels. We conducted a cross-sectional study in three districts of Nepal: Banke, Rupandehi and Udayapur. Udayapur district had been vaccinated against JE most recently (2009), but had been the focus of only one campaign, compared with two in Banke and three in Rupandehi. Participants answered a short questionnaire and serum was assayed for anti-JEV and anti-DENV IgM and IgG (by ELISA) and 50% plaque reduction neutralisation titres (PRNT50) against JEV and DENV serotypes 1-4. A titre of ≥1:10 was considered seropositive to the respective virus. JEV neutralising antibody seroprevalence (PRNT50 ≥ 1:10) was 81% in Banke and Rupandehi, but only 41% in Udayapur, despite this district being vaccinated more recently. Sensitivity of ELISA for both anti-JEV and anti-DENV antibodies was low compared with PRNT50. DENV neutralising antibody correlated with the JEV PRNT50 ≥1:10, though the effect was modest. IgM (indicating recent infection) against both viruses was detected in a small number of participants. We also show that DENV IgM is present in Nepali subjects who have not travelled to India, suggesting that DENV may have become established in Nepal. We therefore propose that further JE vaccine campaigns should be considered in Udayapur district, and similar areas that have had fewer vaccination campaigns.
Bibliography:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Current address: London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom.
Current address: Expanded Programme on Immunization Unit, Division of Communicable Diseases, World Health Organization, Regional Office for the Western Pacific, Manila, Philippines
Current address: Department of Biology and Microbiology, South Dakota State University, Brookings, SD, United States of America.
The authors have declared that no competing interests exist.
Current address: IVD World Health Organization Country Office, Dhaka, Bangladesh
TS and MJG also contributed equally to this work.
Current address: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
ISSN:1935-2735
1935-2727
1935-2735
DOI:10.1371/journal.pntd.0007269